Cannabis Use in Bariatric Surgery: Risks and Management Pathway

Overview

Cannabis use is prevalent among bariatric surgery patients and poses unique perioperative risks due to its effects on cardiovascular, pulmonary, and neurological systems. Current guidelines lack specific recommendations for cannabis management in this population, prompting the need for a tailored clinical pathway.

Background

Bariatric surgery patients undergo extensive preoperative evaluation to optimize outcomes and minimize complications. Substance use disorders, including cannabis use, are recognized as potential contraindications to surgery due to their impact on surgical risk and recovery. Cannabis, containing psychoactive THC and non-psychoactive CBD, affects multiple organ systems relevant to anesthesia and postoperative care. With increasing legalization and use, understanding cannabis's perioperative implications in bariatric patients is critical.

Data Highlights

Key Findings

• Cannabis use affects cardiovascular function with dose-dependent effects: acute low doses cause hypertension and tachycardia, chronic high doses may cause hypotension and bradycardia.
• Patients using cannabis have an increased risk of perioperative myocardial infarction (OR 1.88), likely due to increased oxygen demand and hemodynamic instability.
• Alterations in pulmonary function from cannabis may complicate intraoperative ventilation and postoperative respiratory recovery.
• Bariatric patients have a 6–8% prevalence of cannabis use, necessitating routine screening and management consideration.
• Current bariatric surgery guidelines exclude patients with substance use disorders but lack specific protocols for cannabis use.
• Anesthesia recommendations include avoiding cannabinoids within 72 hours before surgery to reduce perioperative risks.

Clinical Implications

Clinicians should systematically screen bariatric surgery candidates for cannabis use and counsel on perioperative risks, including cardiovascular and respiratory complications. A multidisciplinary approach involving anesthesiology, surgery, and psychiatry is essential to optimize timing of surgery and manage cannabis use. Avoidance of cannabinoids at least 72 hours preoperatively is advised to mitigate hemodynamic and respiratory risks.

Conclusion

Cannabis use in bariatric surgery patients presents unique perioperative challenges that require targeted management strategies. Development and implementation of standardized clinical pathways will improve patient safety and surgical outcomes in this growing patient population.

References

1. American Society for Metabolic and Bariatric Surgery 2021 -- Bariatric Surgery Statistics
2. ASMBS Clinical Practice Guidelines 2019 -- Non-surgical Support for Bariatric Patients
3. Volkow et al. 2019 -- Cannabis Use and Addiction Risk
4. Jain et al. 2020 -- Perioperative Risks of Cannabis Use